Pharmacology

Pharmacology is the study of how drugs interact with living organisms, how they produce effects, and how organisms absorb, distribute, transform, and eliminate them. It investigates both therapeutic effects and harmful reactions, providing a scientific basis for developing medicines and understanding their use in medicine. Its scope includes laboratory research on drug mechanisms and studies of drug responses in humans. (bps.ac.uk)

Scope and related disciplines

Pharmacology asks what a drug acts on, how that interaction changes biological function, and how the response depends on exposure. Its two central areas are pharmacodynamics, concerning drug effects, and pharmacokinetics, concerning the time course of drugs in the body. Together, they connect an administered dose with the concentration reaching its site of action and the resulting response. (pharmacologyeducation.org)

Pharmacology is distinct from pharmacy, which encompasses the preparation and provision of medicines and associated professional services. The fields overlap in their concern with medicine use, but pharmacology principally investigates how drugs work. Clinical pharmacology focuses on the relationship between drugs and humans, including the study of existing medicines and the development of new treatments. (bps.ac.uk)

Historical development

Modern experimental pharmacology emerged in the nineteenth century as drug research shifted from describing medicinal substances to investigating their actions through controlled experiments. Rudolf Buchheim and his student Oswald Schmiedeberg were central to this development. Buchheim began his work at the University of Dorpat, now Tartu in Estonia, in 1847; Schmiedeberg subsequently developed an influential research and training program in Strasbourg, becoming director of its pharmacological institute in 1872. (pmc.ncbi.nlm.nih.gov)

The discipline became increasingly organized through specialist journals and scientific societies. The Journal of Pharmacology and Experimental Therapeutics was founded in 1909, and the British Pharmacological Society was established in 1931. The society launched the British Journal of Clinical Pharmacology in 1974, reflecting the institutional development of drug research in humans alongside experimental pharmacology. (bps.ac.uk)

Pharmacodynamics: mechanisms and responses

Many drugs act by binding to biological targets. Major target classes include receptors, enzymes, ion channels, and transporter proteins. Receptors recognize a ligand and connect its binding to a biological response; other targets can alter chemical reactions, ion movement, or the transport of substances. The term “receptor” is sometimes used broadly in pharmacology, although these target classes have distinct functions. (pharmacologyeducation.ed.ac.uk)

Receptor-active drugs are commonly described as:

• Agonists, which activate a receptor.
• Partial agonists, which produce a smaller maximum response than a full agonist in the same experimental system.
• Antagonists, which block agonist-mediated activation.

A reversible competitive antagonist competes for binding at the same receptor site. Under suitable experimental conditions, increasing agonist concentration can overcome this competition. Other forms of antagonism can reduce the maximum response achievable by an agonist. (pharmacologyeducation.ed.ac.uk)

The dose–response relationship describes how an effect changes with dose or concentration. Potency concerns the amount needed to produce a specified effect, whereas efficacy concerns the magnitude of response a drug can produce in a given system. Greater potency does not necessarily mean greater maximum efficacy. Repeated exposure can also reduce responsiveness through desensitization. (pharmacologyeducation.ed.ac.uk)

Pharmacokinetics: the course of drug exposure

Pharmacokinetics commonly organizes drug handling into four processes, abbreviated ADME:

Intravenous administration introduces a drug directly into the bloodstream, whereas other routes generally require absorption across tissue barriers. Distribution influences access to sites of action. Metabolism occurs in several organs, particularly the liver, and excretion commonly occurs through urine or bile. (pharmacologyeducation.ed.ac.uk)

Concentration–time measurements show how exposure rises and falls after administration. The half-life describes the time required for concentration to fall by half under the relevant kinetic conditions. With repeated dosing, drug concentrations may accumulate and eventually reach a steady-state pattern. These relationships help explain differences in onset, duration, and response between drugs and between individuals. (pharmacologyeducation.ed.ac.uk)

Variation, interactions, and safety

Drug responses vary with age, disease, genetic characteristics, other medicines, and environmental factors. Variation can arise from differences in drug handling or from differences in the biological response at a given concentration. Consequently, the same dose does not necessarily produce the same exposure or effect in every person. (pharmacologyeducation.org)

Pharmacogenomics examines how genomic variation influences medication responses. Variants may help explain differences in effectiveness or susceptibility to adverse reactions. Genetic information is one component of this assessment: it cannot identify a universally “perfect” medicine, and informative testing is not available for every drug or condition. (genome.gov)

Drug–drug interactions may change pharmacokinetics or pharmacodynamics. For example, one medicine can alter the handling of another, or drugs can compete at receptors and modify downstream responses. (bps.ac.uk)

The therapeutic index expresses the separation between doses producing a desired effect and those producing a specified harmful effect. A narrow separation makes balancing benefit and harm more difficult. This measure does not capture every aspect of safety, because medicines can have multiple adverse effects and individual responses differ. (pharmacologyeducation.ed.ac.uk)

Drug development and continuing evaluation

Pharmacology contributes throughout drug development, from laboratory discovery and preclinical investigation to human studies and post-approval monitoring. Laboratory and animal findings address mechanisms and initial safety questions, while human studies establish evidence about clinical effects. Regulatory review evaluates the submitted evidence rather than treating laboratory activity alone as proof of therapeutic usefulness. (fda.gov)

Human clinical research is commonly organized into phases. Phase I emphasizes safety and dosage; Phase II investigates efficacy and additional safety questions; Phase III gathers larger-scale evidence about benefit and adverse reactions. Phase IV studies take place after approval. Ethical review and informed consent are integral protections for research participants. (fda.gov)

Evaluation continues after a medicine enters use. Pharmacovigilance concerns detecting, assessing, understanding, and preventing adverse effects and other medicine-related problems. It complements clinical trials by supporting continuing assessment of medicines and vaccines during their use in wider populations. (who.int)

References

1. What is pharmacology? — British Pharmacological Societybps.ac.uk
2. Pharmacodynamics — IUPHAR Pharmacology Education Projectpharmacologyeducation.org
3. Oswald Schmiedeberg (1838–1921): Ninth Pharmacologic-Historical Forum, 2024, Munich, Germanypmc.ncbi.nlm.nih.gov
4. Our history — British Pharmacological Societybps.ac.uk
5. Clinical Pharmacology Skills Alliance spending review representationbps.ac.uk
6. Pharmacogenomics Fact Sheet — National Human Genome Research Institutegenome.gov
7. Overview of Pharmacodynamics — MSD Manual Professional Editionmsdmanuals.com
8. The Drug Development Process — FDAfda.gov